Borderline resectable pancreatic cancer: Certainties and controversies

Table 2 Systematic reviews and meta-analysis on neoadjuvant treatment for borderline resectable pancreatic ductal adenocarcinoma

Ref.	N° of studies	N° of included patients	Tumour	NAT regimen	RT	Included studies
Gillen et al[20], 2010	111	4394	R-PDAC, BR-PDAC, LA-PDAC	Gem, 5-FU, 5-FU + Mytomin C, 5-FU + Ox, Gem + Ox, taxanes	+/-	Prospective, retrospective
Tang et al[15], 2015	18	9591	BR-PDAC	FOLFIRINOX, Cap, Gem, Gem + Docetaxel, Gem + S1, 5-FU + Pac + Gem + Cap, Gem + Ox	+/-	Prospective
Dhir et al[17], 2017	96	5520	R-PDAC, BR-PDAC, LA-PDAC	FOLFIRINOX, Cap, Gem, 5-FU, Gem + Docetaxel, Gem + S1, Pac + Gem + Cap, Gem + Ox, Gem + Pac	+/-	Prospective, retrospective, RCT
Versteijne et al[19], 2018	38	3484, 17381	R-PDAC, BR-PDAC	NR	+/-	Prospective, retrospective, RCT
Pan et al[21], 2019	17	2286	R-PDAC, BR-PDAC	5-FU + Cis, Cap, 5-FU, Gem, Gem + Cap, Gem + Cis, Gem + S1, Gem + Pac	+/-	Prospective, retrospective, RCT
Cloyd et al[22], 2020	6	850, 4111	R-PDAC, BR-PDAC	Gem, Gem+S1	+/-	RCT

¹Patients who underwent NAT.

BR: Borderline resectable; LA: Locally advanced; PDAC: Pancreatic ductal adenocarcinoma; NR: Not reported; Cap: Capecitabine; Gem: Gemcitabine; 5-FU: 5-fluorouracil; Pac: Paclitaxel; Ox: Oxaliplatin; Cis: Cisplatin; RCT: Randomized controlled trial.